Seven Fleet Capital Management LP Buys 54,254 Shares of Climb Bio, Inc. $CLYM

Seven Fleet Capital Management LP increased its stake in Climb Bio, Inc. (NASDAQ:CLYM) by 71.0% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 130,654 shares of the company’s stock after purchasing an additional 54,254 shares during the quarter. Seven Fleet Capital Management LP owned approximately 0.23% of Climb Bio worth $895,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of CLYM. ArchPoint Investors purchased a new stake in Climb Bio in the fourth quarter worth about $486,000. 683 Capital Management LLC purchased a new position in shares of Climb Bio during the 4th quarter valued at about $807,000. ADAR1 Capital Management LLC lifted its position in shares of Climb Bio by 11.9% during the 3rd quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock valued at $268,000 after buying an additional 14,210 shares in the last quarter. Hudson Bay Capital Management LP bought a new position in shares of Climb Bio during the 4th quarter valued at approximately $195,000. Finally, Jane Street Group LLC bought a new position in shares of Climb Bio during the 2nd quarter valued at approximately $184,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Trading Down 1.5%

Shares of CLYM opened at $11.90 on Friday. The business’s 50 day moving average is $12.20 and its 200 day moving average is $8.99. The company has a market capitalization of $681.39 million, a PE ratio of -15.26 and a beta of 0.07. Climb Bio, Inc. has a 12-month low of $1.36 and a 12-month high of $14.41.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.06. Equities research analysts predict that Climb Bio, Inc. will post -0.87 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CLYM. Chardan Capital started coverage on shares of Climb Bio in a report on Tuesday, May 5th. They set a “buy” rating and a $22.00 price target on the stock. Oppenheimer increased their price objective on shares of Climb Bio from $10.00 to $18.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 21st. Robert W. Baird set a $21.00 price objective on shares of Climb Bio in a research report on Wednesday, May 6th. Wall Street Zen upgraded shares of Climb Bio from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Mizuho started coverage on shares of Climb Bio in a research note on Wednesday, April 15th. They set an “outperform” rating and a $18.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $22.00.

Climb Bio Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.